Phase 3 trial of cemiplimab (Libtayo®) monotherapy in advanced cervical cancer stopped early due to positive overall survival data

The study (n=608 with squamous cell carcinoma and adenocarcinoma) demonstrated a 31% reduced risk of mortality in the total population vs chemotherapy (median survival, 12 vs 8.5 months; HR 0.69; 95% CI: 0.56-0.84; p<0.001).

Biospace Inc.